GlassScriptPhysician profile
Amanda Blevins
NPI 1497203145
$1,258.46
in general payments reported to CMS, 2019-2025
21 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $228 · 2023: $339 · 2024: $374 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $280.43 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $137.11 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $114.23 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $112.57 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.09 | 2023-2025 | |
| Astellas Pharma US INC | $72.93 | 2023-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $70.90 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $47.13 | 2023 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $44.49 | 2022-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.47 | 2022-2024 | Ofev, Jardiance |
| Daiichi Sankyo INC. | $37.33 | 2023-2024 | Injectafer |
| Abbott Laboratories | $36.08 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $30.21 | 2021-2022 | |
| Kyowa Kirin, INC. | $25.01 | 2023 | Crysvita |
| Esperion Therapeutics, INC. | $19.55 | 2023 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $18.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.71 | 2023 | Gvoke Hypopen |
| Boston Scientific Corporation | $14.45 | 2021 | |
| Exact Sciences Corporation | $14.19 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $13.81 | 2022 | |
| Janssen Biotech, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Blevins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.